These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 29431311)
1. A Case Report of Metastatic Primary Thyroid Leiomyosarcoma Treated with Pazopanib. Kushnir I; Soyfer V; Merimsky O Isr Med Assoc J; 2018 Feb; 20(2):125-126. PubMed ID: 29431311 [No Abstract] [Full Text] [Related]
2. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study. Nakamura T; Matsumine A; Kawai A; Araki N; Goto T; Yonemoto T; Sugiura H; Nishida Y; Hiraga H; Honoki K; Yasuda T; Boku S; Sudo A; Ueda T Cancer; 2016 May; 122(9):1408-16. PubMed ID: 26970174 [TBL] [Abstract][Full Text] [Related]
3. A phase I study of pazopanib in combination with escalating doses of 131I in patients with well-differentiated thyroid carcinoma borderline refractory to radioiodine. Chow LQ; Santana-Davila R; Pantel A; Roth M; Anderson LN; Failor A; Doot R; Mankoff D PLoS One; 2017; 12(6):e0178325. PubMed ID: 28662033 [TBL] [Abstract][Full Text] [Related]
4. Harnessing soft tissue sarcoma with low-dose pazopanib - a matter of blood levels. Groenland SL; Katz D; Huitema ADR; Steeghs N BMC Cancer; 2018 Dec; 18(1):1200. PubMed ID: 30509247 [TBL] [Abstract][Full Text] [Related]
5. Pazopanib-induced regression of metastatic cardiac tumor from uterine leiomyosarcoma evaluated by cardiac computed tomography. Yoshihara S Ginekol Pol; 2024; 95(2):169-170. PubMed ID: 37642247 [No Abstract] [Full Text] [Related]
6. A Case of Uterine Leiomyosarcoma with Long-Term Disease Control by Pazopanib. Nagamata S; Ebina Y; Yamano Y; Miyamoto T; Nishijima M; Yamada H Kobe J Med Sci; 2016 Jul; 62(2):E45-8. PubMed ID: 27578036 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series. Yoo KH; Kim HS; Lee SJ; Park SH; Kim SJ; Kim SH; La Choi Y; Shin KH; Cho YJ; Lee J; Rha SY BMC Cancer; 2015 Mar; 15():154. PubMed ID: 25885855 [TBL] [Abstract][Full Text] [Related]
8. Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features. Kim JH; Park I; Lee JL Cancer Chemother Pharmacol; 2016 Aug; 78(2):325-32. PubMed ID: 27324136 [TBL] [Abstract][Full Text] [Related]
9. Trametinib with and without pazopanib has potent preclinical activity in thyroid cancer. Ball DW; Jin N; Xue P; Bhan S; Ahmed SR; Rosen DM; Schayowitz A; Clark DP; Nelkin BD Oncol Rep; 2015 Nov; 34(5):2319-24. PubMed ID: 26324075 [TBL] [Abstract][Full Text] [Related]
10. Pazopanib as a second line treatment for uterine and ovarian carcinosarcoma: a single institutional study. Nishikawa T; Hasegawa K; Yabuno A; Yoshida H; Yasuda M; Kozawa E; Fujiwara K J Gynecol Oncol; 2017 Jan; 28(1):e25. PubMed ID: 27958685 [No Abstract] [Full Text] [Related]
11. Reintroducing Pazopanib Reverses the Primary Resistance of Nivolumab in a Patient With Metastatic Clear-cell Renal Cell Carcinoma. Yu-Li Su H Clin Genitourin Cancer; 2018 Apr; 16(2):114-116. PubMed ID: 29329663 [No Abstract] [Full Text] [Related]
12. Metastatic leiomyosarcoma in brain and heart. Adachi M; Wellmann KF; Garcia R J Pathol; 1969 Aug; 98(4):294-6. PubMed ID: 5358278 [No Abstract] [Full Text] [Related]
13. Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review. Boudou-Rouquette P; Tlemsani C; Blanchet B; Huillard O; Jouinot A; Arrondeau J; Thomas-Schoemann A; Vidal M; Alexandre J; Goldwasser F Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1433-1444. PubMed ID: 27556889 [TBL] [Abstract][Full Text] [Related]
14. Pulmonary carcinosarcoma showing an obvious response to pazopanib: a case report. Tanimoto A; Takeuchi S; Kotani H; Yamashita K; Yamada T; Ohtsubo K; Ebi H; Ikeda H; Yano S BMC Pulm Med; 2018 Dec; 18(1):193. PubMed ID: 30541518 [TBL] [Abstract][Full Text] [Related]
15. Leiomyosarcoma of the saphenous vein. Gross E; Horton MA J Pathol; 1975 May; 116(1):37-41. PubMed ID: 1159575 [TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant Therapy in Differentiated Thyroid Cancer. Dang RP; McFarland D; Le VH; Camille N; Miles BA; Teng MS; Genden EM; Misiukiewicz KJ Int J Surg Oncol; 2016; 2016():3743420. PubMed ID: 27747102 [No Abstract] [Full Text] [Related]
18. Pharmacokinetic drug evaluation of pazopanib for the treatment of uterine leiomyosarcomas. Ferrero S; Leone Roberti Maggiore U; Aiello N; Barra F; Ditto A; Bogani G; Raspagliesi F; Lorusso D Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):881-889. PubMed ID: 28678537 [TBL] [Abstract][Full Text] [Related]
19. Promising effects of pazopanib with radiation on an advanced prostate leiomyosarcoma after failure of systemic chemotherapy. Lin MH; Hsiao HH Kaohsiung J Med Sci; 2019 May; 35(5):317-318. PubMed ID: 30887661 [No Abstract] [Full Text] [Related]
20. Metastatic leiomyosarcoma of the thyroid: a case report. Wang TY; Lee CH; Yang AH; P'eng FK; Lui WY Zhonghua Yi Xue Za Zhi (Taipei); 1998 Jun; 61(6):353-7. PubMed ID: 9684512 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]